Drug Details

General Information of the Drug (ID: DR8879)
Name
Praziquantel
Synonyms
praziquantel; 55268-74-1; Biltricide; Droncit; Pyquiton; Cesol; Embay 8440; Azinox; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; MLS000038419; Praziquantel (Biltricide); MFCD00058531; SMR000037139; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; Cutter Tape Tabs; 2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one; 4H-Pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; Praziquantelum; Distocide; Prazinon; DSSTox_CID_1182; DSSTox_RID_75995; DSSTox_GSID_21182; Praziquantelum [INN-Latin]; Cutter; Biltricide (TN); CCRIS 4114; SR-01000003100; EINECS 259-559-6; BRN 0761557; Bay-8440; Praziquantel (JAN/USP/INN); EMBAY-8440; Praziquantel,(S); NCGC00016877-01; Prestwick_402; CAS-55268-74-1; (+-)-Praziquantel; ACMC-20emeg; Praziquantel [USAN:USP:INN:BAN:JAN]; Spectrum_001119; Opera_ID_378; Prestwick0_000260; Prestwick1_000260; Prestwick2_000260; Prestwick3_000260; Spectrum2_001288; Spectrum3_000550; Spectrum4_000482; Spectrum5_001064; CHEMBL976; P 4668; cid_4891; Lopac0_000909; Oprea1_163497; SCHEMBL44153; BSPBio_000080; BSPBio_002199; KBioGR_000963; KBioSS_001599; 135526-78-2; 5-24-03-00361 (Beilstein Handbook Reference); MLS000028528; MLS001201812; MLS001304085; MLS002548849; MLS006011880; DivK1c_000130; SPECTRUM1500494; SPBio_001295; SPBio_002299; Praziquantel-(cyclohexyl-d11); BPBio1_000088; DTXSID9021182; SCHEMBL16019896; BDBM74574; CHEBI:91583; HMS500G12; KBio1_000130; KBio2_001599; KBio2_004167; KBio2_006735; KBio3_001699; NINDS_000130; HMS1568D22; HMS1920J06; HMS2090J19; HMS2092A09; HMS2095D22; HMS3259K07; HMS3262F20; HMS3655O19; HMS3712D22; Pharmakon1600-01500494; AMY16524; BCP17829; BCP28525; BCP30228; HY-B0244; Tox21_110660; Tox21_201950; Tox21_302927; Tox21_500909; CCG-39773; CP0098; NSC757285; Praziquantel, anthelminic, neurogenic; s1691; STK030186; AKOS000541869; AKOS016398525; Tox21_110660_1; AC-8426; DB01058; LP00909; MCULE-1638759858; NC00468; NE56665; NSC 757285; NSC-757285; SDCCGSBI-0050884.P005; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; IDI1_000130; NCGC00015818-04; NCGC00015818-05; NCGC00015818-06; NCGC00015818-07; NCGC00015818-08; NCGC00015818-11; NCGC00015818-12; NCGC00015818-14; NCGC00015818-15; NCGC00015818-26; NCGC00089733-02; NCGC00089733-03; NCGC00089733-04; NCGC00089733-05; NCGC00256422-01; NCGC00259499-01; NCGC00261594-01; AK161796; AS-12459; SY052322; SBI-0050884.P004; AB0011974; DB-052707; (S)-Praziquantel; Praziquantel, (S)-Isomer; AB00052075; EU-0100909; FT-0630676; P2125; ST50904686; SW196645-3; 1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-; C07367; D00471; J10194; AB00052075-13; AB00052075-15; AB00052075_16; AB00052075_17; Praziquantel, VETRANAL(TM), analytical standard; 268P741; Q424145; Praziquantel, Antibiotic for Culture Media Use Only; Q-201612; SR-01000003100-3; SR-01000003100-5; SR-01000003100-7; BRD-A21858158-001-05-2; BRD-A21858158-001-16-9; F0037-0136; Z1563145961; Praziquantel, European Pharmacopoeia (EP) Reference Standard; Praziquantel, United States Pharmacopeia (USP) Reference Standard; 10-(cyclohexylcarbonyl)-5,6,7,11a-tetrahydropiperazino[2,1-a]isoquinolin-8-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino-[2,1- a]isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-aisoquinolin-4-one; 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; Praziquantel for system suitability, European Pharmacopoeia (EP) Reference Standard; Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material
    Click to Show/Hide
Molecular Type
Small molecule
Disease Flatworm infection [ICD-11: 1F70-1F86] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H24N2O2
PubChem CID
4891
Canonical SMILES
C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
InChI
1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2
InChIKey
FSVJFNAIGNNGKK-UHFFFAOYSA-N
CAS Number
CAS 55268-74-1
ChEBI ID
CHEBI:91583
TTD Drug ID
D0L9ZR
DrugBank ID
DB01058
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Xanthohumol      Humulus lupulus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression CD44  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation p38 beta  Molecule Info 
Pathway MAP
Down-regulation Expression TFRC  Molecule Info 
Pathway MAP
                    In-vivo Model Six- to eight-week-old male Syrian golden hamsters were used in this study.
                    Experimental
                    Result(s)		 XN administered in combination with PZ could efficiently prevent CCA development and hence provide potential chemopreventive benefits in Ov-induced cholangiocarcinogenesis.
Target and Pathway
Target(s) Glutathione-S-transferase (HPGDS)  Molecule Info  [3]
BioCyc C20 prostanoid biosynthesis Click to Show/Hide
KEGG Pathway Arachidonic acid metabolism Click to Show/Hide
2 Metabolic pathways
WikiPathways Arachidonic acid metabolism Click to Show/Hide
2 Aryl Hydrocarbon Receptor
3 Integrated Pancreatic Cancer Pathway
References
Reference 1 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
Reference 2 Antifibrotic effect of xanthohumol in combination with praziquantel is associated with altered redox status and reduced iron accumulation during liver fluke-associated cholangiocarcinogenesis. PeerJ. 2018 Jan 22;6:e4281.
Reference 3 X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link